Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016
Abstract Background There has been much variation between epidemiological studies that report the prevalence of ankylosing spondylitis (AS). This study aimed to analyze the diagnostic prevalence rates and treatment patterns of male and female AS patients in the United States adult insured population...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-09-01
|
| Series: | BMC Rheumatology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41927-019-0086-3 |
| _version_ | 1818061517360201728 |
|---|---|
| author | Jessica Walsh Theresa Hunter Krista Schroeder David Sandoval Rebecca Bolce |
| author_facet | Jessica Walsh Theresa Hunter Krista Schroeder David Sandoval Rebecca Bolce |
| author_sort | Jessica Walsh |
| collection | DOAJ |
| description | Abstract Background There has been much variation between epidemiological studies that report the prevalence of ankylosing spondylitis (AS). This study aimed to analyze the diagnostic prevalence rates and treatment patterns of male and female AS patients in the United States adult insured population from 2006 to 2016. Methods Trends in AS prevalence were calculated for the 11-year period covering January 1, 2006 to December 31, 2016. Adult (18+ years old) AS patients were included in this retrospective analysis of medical and pharmacy claims data from the IBM Marketscan Commercial, Medicaid and Medicare-Supplemental Claims database. Prevalence was determined as having ≥1 AS diagnostic codes (ICD-9:720.0; ICD-10:M45.x). Trends in treatment patterns were also analyzed and stratified by gender. Results The AS prevalence increased from 0.04 to 0.09% from 2006 to 2016. The mean age between 2006 and 2016 ranged from 49.52–50.00 years. In 2006, approximately 40% of AS patients were female, while in 2016 over 47% of AS patients were female. Rates of use of TNF inhibitors and oral glucocorticoids increased, while NSAIDs and non-biologic DMARDs (sulfasalazine & methotrexate) rates decreased. Opioid use rates were stable. In 2016, males were more likely to be prescribed biologics, while females were more likely to be prescribed methotrexate, sulfasalazine, NSAIDs, muscle relaxants, anticonvulsants, opioids, and glucocorticoids. Conclusions The prevalence of AS diagnosis codes more than doubled between 2006 and 2016, but the very low prevalence suggests that AS continues to be underdiagnosed and under-addressed in routine clinical practice. Despite the increase in female AS patients, females were less likely to be prescribed biologics compared to male AS patients. |
| first_indexed | 2024-12-10T13:49:34Z |
| format | Article |
| id | doaj.art-5e25cf91ae5c4a278c9a2b502671a8f0 |
| institution | Directory Open Access Journal |
| issn | 2520-1026 |
| language | English |
| last_indexed | 2024-12-10T13:49:34Z |
| publishDate | 2019-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Rheumatology |
| spelling | doaj.art-5e25cf91ae5c4a278c9a2b502671a8f02022-12-22T01:46:17ZengBMCBMC Rheumatology2520-10262019-09-01311610.1186/s41927-019-0086-3Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016Jessica Walsh0Theresa Hunter1Krista Schroeder2David Sandoval3Rebecca Bolce4University of UtahEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyEli Lilly and CompanyAbstract Background There has been much variation between epidemiological studies that report the prevalence of ankylosing spondylitis (AS). This study aimed to analyze the diagnostic prevalence rates and treatment patterns of male and female AS patients in the United States adult insured population from 2006 to 2016. Methods Trends in AS prevalence were calculated for the 11-year period covering January 1, 2006 to December 31, 2016. Adult (18+ years old) AS patients were included in this retrospective analysis of medical and pharmacy claims data from the IBM Marketscan Commercial, Medicaid and Medicare-Supplemental Claims database. Prevalence was determined as having ≥1 AS diagnostic codes (ICD-9:720.0; ICD-10:M45.x). Trends in treatment patterns were also analyzed and stratified by gender. Results The AS prevalence increased from 0.04 to 0.09% from 2006 to 2016. The mean age between 2006 and 2016 ranged from 49.52–50.00 years. In 2006, approximately 40% of AS patients were female, while in 2016 over 47% of AS patients were female. Rates of use of TNF inhibitors and oral glucocorticoids increased, while NSAIDs and non-biologic DMARDs (sulfasalazine & methotrexate) rates decreased. Opioid use rates were stable. In 2016, males were more likely to be prescribed biologics, while females were more likely to be prescribed methotrexate, sulfasalazine, NSAIDs, muscle relaxants, anticonvulsants, opioids, and glucocorticoids. Conclusions The prevalence of AS diagnosis codes more than doubled between 2006 and 2016, but the very low prevalence suggests that AS continues to be underdiagnosed and under-addressed in routine clinical practice. Despite the increase in female AS patients, females were less likely to be prescribed biologics compared to male AS patients.http://link.springer.com/article/10.1186/s41927-019-0086-3Ankylosing spondylitisPrevalenceTreatment patterns |
| spellingShingle | Jessica Walsh Theresa Hunter Krista Schroeder David Sandoval Rebecca Bolce Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016 BMC Rheumatology Ankylosing spondylitis Prevalence Treatment patterns |
| title | Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016 |
| title_full | Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016 |
| title_fullStr | Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016 |
| title_full_unstemmed | Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016 |
| title_short | Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016 |
| title_sort | trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the united states 2006 2016 |
| topic | Ankylosing spondylitis Prevalence Treatment patterns |
| url | http://link.springer.com/article/10.1186/s41927-019-0086-3 |
| work_keys_str_mv | AT jessicawalsh trendsindiagnosticprevalenceandtreatmentpatternsofmaleandfemaleankylosingspondylitispatientsintheunitedstates20062016 AT theresahunter trendsindiagnosticprevalenceandtreatmentpatternsofmaleandfemaleankylosingspondylitispatientsintheunitedstates20062016 AT kristaschroeder trendsindiagnosticprevalenceandtreatmentpatternsofmaleandfemaleankylosingspondylitispatientsintheunitedstates20062016 AT davidsandoval trendsindiagnosticprevalenceandtreatmentpatternsofmaleandfemaleankylosingspondylitispatientsintheunitedstates20062016 AT rebeccabolce trendsindiagnosticprevalenceandtreatmentpatternsofmaleandfemaleankylosingspondylitispatientsintheunitedstates20062016 |